Cirrhotic cardiomyopathy

Clinical Liver Disease

Volumn 2, Issue 3, 2013, Pages 99-101

  Bernardi, Mauro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; AMIODARONE; ANGIOTENSIN II; BEPRIDIL; BETA ADRENERGIC RECEPTOR; CALCIUM; CLARITHROMYCIN; CYCLIC AMP; CYTOKINE; DISOPYRAMIDE; DOFETILIDE; DOMPERIDONE; ENDOCANNABINOID; ERYTHROMYCIN; GUANINE NUCLEOTIDE BINDING PROTEIN; IBUTILIDE; LIDOFLAZINE; MOXIFLOXACIN; NITRIC OXIDE; PENTAMIDINE; PHOSPHOLIPASE; PROCAINAMIDE; QUINIDINE; SODIUM; SOTALOL; SPARFLOXACIN; TROPONIN C; UNINDEXED DRUG; VERAPAMIL; ARSENIC TRIOXIDE; CHLORPROMAZINE; CISAPRIDE; DROPERIDOL; HALOPERIDOL; MESORIDAZINE; METHADONE; PIMOZIDE; THIORIDAZINE;

ADRENERGIC SYSTEM; BACTERIAL INFECTION; CALCIUM CHANNELOPATHY; CARDIOMYOPATHY; CHRONOTROPISM; CIRRHOTIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; ELECTROPHYSIOLOGY; EXERCISE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM ENLARGEMENT; HEART CONTRACTION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART OUTPUT; HEART VENTRICLE ARRHYTHMIA; HUMAN; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIGNAL TRANSDUCTION; SODIUM CHANNELOPATHY; STRESS; SUDDEN DEATH; SYSTOLIC DYSFUNCTION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VASCULAR RESISTANCE; ARRHYTHMOGENESIS; DRUG USE; HEART DISEASE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION;

EID: 84902153033     PISSN: None     EISSN: 20462484     Source Type: Journal    
DOI: 10.1002/cld.141     Document Type: Review

References (10)

1. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008; 28: 59-69.
2. Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974; 49: 754-760.
3. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001; 49: 268-275.
4. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009; 3: 294-304.
5. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut 2007; 56: 869-875.
6. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006; 44: 994-1002.
7. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28-34.
8. Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53: 179-190.
9. Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007; 46: 935-946.
10. Trevisani F, Di Micoli A, Zambruni A, Biselli M, Santi V, Erroi V, et al. QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int 2012; 32: 1510-1515.